Medtronic revamps Japanese management:
This article was originally published in Clinica
Executive Summary
Medtronic Japan has asked all directors aged over 56 to resign and has promoted the cardiac division director, Hiroshi Kudo, to vice-president and representative director, commercial operations, reports the Japan Medical Review. At the same time the company has ceased Japanese production of implantable pacemakers, citing high labour costs and changes in insurance reimbursement. Mr Kudo said that the management changes represent a "rejuvenation" of the company.
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.